Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by labumbaon Apr 22, 2009 8:24pm
335 Views
Post# 15937755

RE: Snrkid says

RE: Snrkid saysFrom my recollection, the  "CIS/TRANS mix to a TRANS " formulation was initiated by Roche with their technical support....and that was what Roche wanted. Consequently, ISA made a change for the betterment of the drug that delayed the timeline of this drug development. Furthermore, Roche's scientific team also made a presentation with an abstract on cis and Trans isomers by refering to  ISA's method of isomer change. In other words, Roche did have some input on this matter.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities